HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China

On 20 November 2026, HENGRUI PHARMA (01276.HK) said China accepted a filing for hetrombopag olamine in liver disease patients with low blood platelets.
Key Highlights:
  • The NMPA accepted the new-indication filing under acceptance number CXHS2600158 at the marketing stage.
  • The indication covers chronic liver disease-associated thrombocytopenia in adults before elective invasive procedures.

NewTimeSpace News: On 20 November 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276) said in an overseas regulatory announcement under Rule 13.10B that the NMPA had accepted its marketing application for a new indication of hetrombopag olamine tablets, under acceptance number CXHS2600158. The proposed indication is chronic liver disease-associated thrombocytopenia in adults scheduled for elective invasive procedures, including diagnostic ones.

The filing rests on a multicentre, randomised, double-blind, placebo-controlled Phase III trial (SHR8735-302) led by Professor Zhou Jian of Zhongshan Hospital, Fudan University, with 21 mainland sites and 127 patients; the primary endpoint was met in August 2026, with the treatment arm significantly better and safety favourable. Comparable products sold about USD 2.222 billion globally in 2025, and cumulative R&D spending was about RMB 668.2 million (unaudited).

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.